Search results for "Platelet Aggregation"

showing 10 items of 155 documents

Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle.

1997

We investigated the effects of isoliquiritigenin and YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole) on tension in endothelial-free rat aortic rings precontracted with phenylephrine (3 microM). Both compounds induced a concentration-dependent relaxation (EC50 of YC-1 1.9 microM and of isoliquiritigenin 9.4 microM). The effects developed faster with YC-1 than with isoliquiritigenin, and the effects of YC-1 were potentiated by isoliquiritigenin (10 microM). 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (30 microM) inhibited the effect of YC-1, but not of isoliquiritigenin. These results suggest that the effects of YC-1 are due to stimulation of soluble guanylyl cyclase activity, whereas …

Malemedicine.medical_specialtyIndazolesPhosphodiesterase InhibitorsMuscle RelaxationStimulationMuscle Smooth VascularRats Sprague-Dawleychemistry.chemical_compoundChalconeChalconesAldehyde ReductaseInternal medicinemedicineAnimalsEnzyme InhibitorsPhenylephrinePharmacologybiologyDose-Response Relationship DrugChemistryBiological activityRatsDose–response relationshipEndocrinologyCarotid ArteriesMechanism of actionEnzyme inhibitorGuanylate Cyclasebiology.proteinFemalemedicine.symptomSoluble guanylyl cyclaseIsoliquiritigeninPlatelet Aggregation Inhibitorsmedicine.drugMuscle ContractionEuropean journal of pharmacology
researchProduct

Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.

2010

408 Positional cerebral ischemia (PCI) is an extremely rare condition in which dramatic central nervous system deficits are triggered by standing in patients with severe stenosis or occlusion of the major brain-supplying blood vessels [1] . Because PCI is generally associated with orthostatic hypotension [2, 3] , a hemodynamic mechanism has been proposed [4] . However, PCI has been reported even in patients without orthostatic hypotension [1] . The treatment is medical, but surgery can be considered in refractory cases (endarterectomy for carotid artery stenosis or either highor low-flow extra-intracranial bypass – for carotid occlusion) [3] . We report a case of PCI associated with middle …

Malemedicine.medical_specialtyMiddle Cerebral ArterySettore MED/09 - Medicina InternaTiclopidinePostureIschemiaHemodynamicsOrthostatic vital signsmedicine.arteryInternal medicineParietal LobeOcclusionmedicineHumansThrombophiliacardiovascular diseasesCerebral perfusion pressureTomography Emission-Computed Single-Photonpositional ischemia Extracranial by-passAspirinCerebral Revascularizationbusiness.industryInfarction Middle Cerebral ArteryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingClopidogrelTemporal ArteriesParesisHemiparesisBlood pressureNeurologyIschemic Attack TransientAnesthesiaMiddle cerebral arteryCardiologyNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCerebrovascular diseases (Basel, Switzerland)
researchProduct

Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo

1993

The aim of our study was to evaluate the platelet antiaggregatory and hemodynamic effects of the stable prostacyclin analog iloprost and the NO-donor SIN-1, an active metabolite of molsidomine. The number of circulating platelets was determined in anesthetized male Wistar rats as a measure of in vivo platelet aggregation. Platelet count decreased from 648 +/- 25 to 476 +/- 15 x 10(3) platelets/microliter and from 578 +/- 36 to 411 +/- 40 (mean +/- SEM) in response to two repetitive injections of collagen (70 micrograms/kg body weight). Treatment with SIN-1 bolus injections (0.3 or 1 mg/kg bw) and/or continuous i.v. infusion of iloprost (0.2 or 0.4 micrograms/kg bw/min) was initiated 15 min …

Malemedicine.medical_specialtyMolsidominePlatelet AggregationPlatelet aggregationBlood PressureProstacyclinNitric Oxidechemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsPlateletIloprostRats WistarAntihypertensive AgentsActive metaboliteChemistryDrug SynergismHematologyRatsEnzyme ActivationEndocrinologyGuanylate CyclaseMolsidomineAdenylyl Cyclase InhibitorsPlatelet Aggregation InhibitorsSignal TransductionIloprostmedicine.drugGuanylate cyclaseThrombosis Research
researchProduct

Improvement of the circulatory function partially accounts for the neuroprotective action of the phytoestrogen genistein in experimental ischemic str…

2012

Abstract We tested the hypothesis that the phytoestrogen genistein protects the brain against ischemic stroke by improving the circulatory function in terms of reduced production of thromboxane A2 and leukocyte–platelet aggregates, and of preserved vascular reactivity. Ischemia-reperfusion (90 min-3 days, intraluminal filament) was induced in male Wistar rats, and functional score and cerebral infarct volume were the end points examined. Genistein (10 mg/kg/day) or vehicle (β-cyclodextrin) was administered at 30 min after ischemia or sham-operation. Production of thromboxane A2 and leukocyte–platelet aggregates, as well as reactivity of carotid artery to U-46619 (thromboxane A2 analogue) an…

Malemedicine.medical_specialtyPlatelet AggregationIschemiaGenisteinPhytoestrogensNeuroprotectionBrain IschemiaThromboxane A2Thromboxane A2chemistry.chemical_compoundInternal medicinemedicineAnimalsPlateletRats WistarStrokePharmacologyChemistrymedicine.diseaseGenisteinRatsStrokeNeuroprotective AgentsEndocrinologyCirculatory systemIschemic strokeEuropean Journal of Pharmacology
researchProduct

Inhibition of Platelet Aggregation Caused by Estrogen Treatment in Patients with Carcinoma of the Prostate

1975

Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.Estrogen therapy for prostatic carcinoma may lead to the development of cardiovascular complications, such as thromb…

Malemedicine.medical_specialtyPlatelet Aggregationmedicine.drug_classUrologyPopulationPharmacologyPlatelet AdhesivenessProstateInternal medicineCarcinomaHumansEndocrine systemMedicineCastrationeducationDiethylstilbestroleducation.field_of_studyAspirinEstradiolbusiness.industryGenitourinary systemProstatic NeoplasmsCancerEstrogensmedicine.diseaseEndocrinologymedicine.anatomical_structureEstrogenbusinessHormoneJournal of Urology
researchProduct

A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions

2018

Aims: The clinical value of percutaneous coronary intervention (PCI) for chronic coronary total occlusions (CTOs) is not established by randomized trials. This study should compare the benefit of PCI vs. optimal medical therapy (OMT) on the health status in patients with at least one CTO.Method and results: Three hundred and ninety-six patients were enrolled in a prospective randomized, multicentre, open-label, and controlled clinical trial to compare the treatment by PCI with OMT with a 2:1 randomization ratio. The primary endpoint was the change in health status assessed by the Seattle angina questionnaire (SAQ) between baseline and 12 months follow-up. Fifty-two percent of patients have …

Malemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyAngina Pectorislaw.inventionAngina03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineClinical endpointHumansPercutaneous transluminal interventioncardiovascular diseases030212 general & internal medicineMyocardial infarctionOptimal medical therapyAgedNitratesbusiness.industryAngina PectoriPercutaneous coronary interventionAngiotensin-Converting Enzyme InhibitorMiddle Agedmedicine.diseaseClinical trialCoronary OcclusionChronic coronary occlusion; EQ-5D; Optimal medical therapy; Percutaneous transluminal intervention; Seattle angina questionnaire; Cardiology and Cardiovascular MedicineConventional PCIChronic DiseaseChronic coronary occlusionQuality of LifeSeattle angina questionnaireFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitors
researchProduct

Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards

2010

Abstract Introduction Current guidelines for ischemic stroke prevention in atrial fibrillation or flutter (AFF) recommend Vitamin K antagonists (VKAs) for patients at high-intermediate risk and aspirin for those at intermediate-low risk. The cost-effectiveness of these treatments was demonstrated also in elderly patients. However, there are several reports that emphasize the underuse of pharmacological prophylaxis of cardio-embolism in patients with AFF in different health care settings. Aims To evaluate the adherence to current guidelines on cardio-embolic prophylaxis in elderly (> 65 years old) patients admitted with an established diagnosis of AFF to the Italian internal medicine wards p…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaVitamin Kantithrombotic therapyNOAntithrombotic prophylaxis Atrial fibrillation Platelet agents Vitamin K antagonistsFibrinolytic AgentsRisk FactorsInternal medicineAntithromboticInternal MedicinemedicineHumansatrial fibrillationRegistriesMedical prescriptionStrokeAgedRetrospective StudiesAged 80 and overAntithrombotic prophylaxis; Atrial fibrillation; Platelet agents; Vitamin K antagonists;guidelines; antithrombotic therapy; atrial fibrillation.AspirinAspirinbusiness.industryantithrombotic prophylaxis; atrial fibrillation; platelet agents; vitamin k antagonistsAtrial fibrillationRetrospective cohort studyplatelet agentsmedicine.diseaseStrokevitamin k antagonistsIntracranial EmbolismItalyPlatelet aggregation inhibitorFemaleGuideline Adherenceantithrombotic prophylaxisbusinessguidelinePlatelet Aggregation InhibitorsFibrinolytic agentatrial fibrillation.medicine.drug
researchProduct

Prestroke antiplatelet therapy and early prognosis in stroke patients: the Dijon Stroke Registry

2012

Background and purpose Previous antiplatelet therapy (APT) in cardiovascular prevention is common in patients with first-ever stroke. We aimed to evaluate the prognostic value of APT on early outcome in stroke patients. Methods All first-ever strokes from 1985 to 2011 were identified from the population-based Stroke Registry of Dijon, France. Demographic features, risk factors, prestroke treatments and clinical information were recorded. Multivariate analyses were performed to evaluate the associations between pre-admission APT and both severe handicap at discharge, and mortality at 1 month and 1 year. Results Among the 4275 patients, 870 (20.4%) were previously treated with APT. Severe han…

Malemedicine.medical_specialtyStroke registryMultivariate analysisPopulationKaplan-Meier EstimateLower riskRisk FactorsInternal medicinemedicineHumansRegistrieseducationStrokeAgedAged 80 and overeducation.field_of_studybusiness.industryHazard ratioOdds ratioMiddle AgedPrognosismedicine.diseaseConfidence intervalSurgeryStrokeEarly DiagnosisTreatment OutcomeNeurologyFemaleFranceNeurology (clinical)businessPlatelet Aggregation InhibitorsEuropean Journal of Neurology
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Subclavian Stenosis/Occlusion in Patients with Subclavian Steal and Previous Bypass of Internal Mammary Interventricular Anterior Artery: Medical or …

2004

There are only a few published studies on the association between subclavian steal syndrome and ischemic heart disease. The objective of this report is to evaluate the efficacy of subclavian stenoocclusion treatment in patients with subclavian steal syndrome (SSS) and previous cor- onary bypass. Over the last 8 years we observed 207 patients who underwent left internal mammary artery–intraventricular artery (LIMA–IVA) bypass graft. Of these, 31 patients were affected by steno-occlusion of the homolateral subclavian artery. Ten patients (group 1) showed latent vertebral-SSS and were pharmacologically treated. Seven patients (group 2) had an intermittent vertebral-SSS; four patients were trea…

Malemedicine.medical_specialtyTiclopidinemedicine.medical_treatmentConstriction PathologicSubclavean stenosis/occlusionAnginaSubclavian Steal SyndromeRestenosisRisk FactorsInternal medicinemedicine.arteryAngioplastymedicineHumanscardiovascular diseasesInternal Mammary-Coronary Artery AnastomosisSubclavian arteryAgedAspirinmedicine.diagnostic_testbusiness.industryAngioplastyStentGeneral MedicineMiddle Agedmedicine.diseaseSurgerybody regionssurgical procedures operativeAngiographycardiovascular systemCardiologyPlatelet aggregation inhibitorFemaleStentsSurgeryCardiology and Cardiovascular MedicinebusinessSubclavian steal syndromePlatelet Aggregation InhibitorsAnnals of Vascular Surgery
researchProduct